Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

MannKind to receive up to $160mm in debt financing from Deerfield Management

Executive Summary

Deerfield Management has agreed to purchase up to $160mm in six-year 9.75% senior secured convertible notes from MannKind Corp. to fund regulatory and commercial activities for the company’s Afrezza inhaled insulin. The financing consists of an up-front payment of $40mm and three $40mm tranches to be received on the following milestones: upon the release of certain Phase III trial results; concurrent with repayment of MannKind’s 3.75% senior convertible notes due 2013; and following FDA approval of Afrezza. In addition, Deerfield paid MannKind $18.9mm in return for rights to receive up to $90mm in strategic and sales milestones relating to the drug.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
Deal Status
  • Final
Deal Type
  • Financing
    • Convertible Debt
    • Private Placement

Related Companies